Safety and efficacy of JWATM204, a novel glypican-3 (GPC3)-targeted chimeric antigen receptor (CAR) T-cell therapy for advanced hepatocellular carcinoma: A phase I dose-escalation study
Cancer Pathogenesis and Therapy · 2026-07 · 4 (4) · 297-309
DOI: 10.1016/j.cpt.2025.12.002 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Pathogenesis and Therapy, 2026-07. Verfasst von Yongqiang Yang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, China. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Beijing Xisike Clinical Oncology Research Foundation, Science Fund for Distinguished Young Scholars of Hubei Province, National Natural Science Foundation of China.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, China.
- Institute of Radiation Oncology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, China.
- Hubei Key Laboratory of Precision Radiation Oncology, Wuhan, Hubei 430022, China.
- Department of Pathology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, China.
Förderung
- Beijing Xisike Clinical Oncology Research Foundation
- Science Fund for Distinguished Young Scholars of Hubei Province
- National Natural Science Foundation of China
- Key Project of Research and Development Plan of Hunan Province
Zitieren
APA
Yang, Y., Tang, J., Wu, Z., Zhang, J., Liu, D., Fan, J., Wu, G., Zhang, T., & Xue, J. (2026). Safety and efficacy of JWATM204, a novel glypican-3 (GPC3)-targeted chimeric antigen receptor (CAR) T-cell therapy for advanced hepatocellular carcinoma: A phase I dose-escalation study. Cancer Pathogenesis and Therapy, 4(4), 297-309. https://doi.org/10.1016/j.cpt.2025.12.002
Vancouver
Yang Y, Tang J, Wu Z, Zhang J, Liu D, Fan J, et al. Safety and efficacy of JWATM204, a novel glypican-3 (GPC3)-targeted chimeric antigen receptor (CAR) T-cell therapy for advanced hepatocellular carcinoma: A phase I dose-escalation study. Cancer Pathogenesis and Therapy. 2026;4(4):297-309. doi:10.1016/j.cpt.2025.12.002
BibTeX
@article{Yang2026,
author = {Yang, Yongqiang and Tang, Jing and Wu, Zilong and Zhang, Jinfeng and Liu, Dongen and Fan, Jun and Wu, Gang and Zhang, Tao and Xue, Jun},
title = {Safety and efficacy of JWATM204, a novel glypican-3 (GPC3)-targeted chimeric antigen receptor (CAR) T-cell therapy for advanced hepatocellular carcinoma: A phase I dose-escalation study},
journal = {Cancer Pathogenesis and Therapy},
year = {2026},
volume = {4},
number = {4},
pages = {297--309},
doi = {10.1016/j.cpt.2025.12.002}
}
EUVIMED